A single dose of a MIV-150/zinc acetate gel provides 24h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24h after gel use

AIDS Research and Human Retroviruses

Volumn 28, Issue 11, 2012, Pages 1476-1484

  Kenney, Jessica ^a   Singer, Rachel ^a   Derby, Nina ^a   Aravantinou, Meropi ^a   Abraham, Ciby J ^a   Menon, Radhika ^a   Seidor, Samantha ^a   Zhang, Shimin ^a   Gettie, Agegnehu ^b   Blanchard, James ^c   Piatak, Michael ^d   Lifson, Jeffrey D ^d   Fernández Romero, José A ^a   Zydowsky, Thomas M ^a   Robbiani, Melissa ^a  

^a POPULATION COUNCIL   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; MIV 150; MIV 150 PLUS ZINC ACETATE PLUS CARRAGEENAN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; ZINC ACETATE; ZINC ACETATE PLUS CARRAGEENAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GEL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SINGLE DRUG DOSE; VAGINITIS; VIREMIA; VIRUS LOAD;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, RECTAL; ANIMALS; ANTI-INFECTIVE AGENTS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; PYRIDINES; RECTUM; RNA-DIRECTED DNA POLYMERASE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; TREATMENT OUTCOME; UREA; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES; ZINC ACETATE;

EID: 84868581069     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0087     Document Type: Article

References (30)

1. Karim QA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science Express published online July 20, 2010.
2. Shattock RJ and Moore JP: Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003;1:25-34.
3. Fernández-Romero JA, et al.: Carrageenan/MIV-150 (PC-815), a combination microbicide. Sexually Transmit Dis 2007;34:9-14.
4. Turville SG, et al.: Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 2008;3:e3162.
5. Ren J and Stammers DK: Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res 2008;134:157-170.
6. Kumel G, et al.: The mechanism of the antiherpetic activity of zinc sulphate. J Gen Virol 1990;71:2989-2997.
7. Haraguchi Y, et al.: Inhibition of HIV-1 infection by zinc group metal compounds. Antivir Res 1999;43:123-133.
8. Arens M and Travis S: Zinc salts inactivate clinical isolates of herpes simplex virus in vitro. J Clin Microbiol 2000;38:1758-1762.
9. Fernandez-Romero JA, et al.: Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge. Antimicrob Agents Chemother 2012;56:358-368.
10. Kenney J, et al.: An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 2011;6:e15835.
11. Singer R, et al.: The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol 2011;85:5504-5512.
12. Animal Welfare Act and Regulation of 2001. Code of Federal Regulations, t., chapter 1, subchapter A: Animals and Animal Products. U.S. Department of Agriculture, Beltsville, MD.
13. Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources Guide for the Care and Use of Laboratory Animals. Vol. Publication no. 85-23 1-83. U.S. Department of Health and Human Services, National Institutes of Health Bethesda, MD, 1985.
14. Cline AN, et al.: Highly sensitive SIV plasma viral load assay: Practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 2005;34:303-312.
15. Smith SM, et al.: Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: Predictive value for disease progression. AIDS Res Hum Retroviruses 1999;15:1691-1701.
16. Parikh UM, et al.: Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 2009;83:10358-10365.
17. Dobard C, et al.: Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol 2012;86:718-725.
18. Shankar AH and Prasad AS: Zinc and immune function: The biological basis of altered resistance to infection. Am J Clin Nutr 1998;68:447S-463S.
19. Mocchegiani E and Muzzioli M: Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections. J Nutr 2000;130:1424S-1431S.
20. Fenstermacher KJ and DeStefano JJ: Mechanism of HIV reverse transcriptase inhibition by zinc: Formation of a highly stable enzyme-(primer-template) complex with profoundly diminished catalytic activity. J Biol Chem 2011;286:40433-40442.
21. Hirano T, et al.: Roles of zinc and zinc signaling in immunity: Zinc as an intracellular signaling molecule. Adv Immunol 2008;97:149-176.
22. Rink L and Kirchner H: Zinc-altered immune function and cytokine production. J Nutr 2000;130:1407S-1411S.
23. Gross M, et al.: Anal sex among HIV-seronegative women at high risk of HIV exposure. The HIVNET Vaccine Preparedness Study 2 Protocol Team. J Acquir Immune Defic Syndr 2000;24:393-398.
24. Pirrone V, et al.: Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1. Virology 2012;J9:33.
25. Pirrone V, et al.: The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res 2011;90:168-182.
26. Crostarosa F, et al.: A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS One 2009;4;e8060.
27. Skoler-Karpoff S, et al.: Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977-1987.
28. McLean CA, et al.: HIV genital shedding and safety of Car-raguard use by HIV-infected women: A crossover trial in Thailand. AIDS 2010;24;717-7 22.
29. Bennett DE, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance:2009 update. PLoS One 2009;4:e4724.
30. Tambuyzer L, et al.: Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir Ther 2009;14:103-109.